glp-1 news 2025 october 16 Trends: Access & Shortages, Insurance Coverage & More Mapping the effectiveness and risks

Understanding these genetic insights helps PlexusDx clinicians select the optimal compound and dosing strategy, potentially reducing overall side-effect burden and improving injection tolerance

Rivera FB, Cruz LLA, Magalong JV et al (2024) Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

P =0.532) and women (IRR, 0.95

They can both influence appetite and digestion timing but through different mechanisms and with very different average effects in human clinical trials

Ibsen S, Schutt CE, Esener S